Table I.

TRP-2-pulsed DC are the most efficient vaccination strategy against the B16 melanoma

VaccineaNo. of InjectionsbTake (protection)cLatency (days)dSurvival (days)e
PBS410 /10 (0)10.1 ± 0.216.9 ± 0.5
DC38 /8 (0)10.7 ± 1.216.1 ± 1.3
DC+ TRP-2181–200110 /10 (0)11.5 ± 0.417.1 ± 0.7
39 /14 (36)18.7 ± 1.423.2 ± 1.1
Vector35 /5 (0)11.4 ± 1.417.8 ± 0.5
TRP-2 DNA110 /10 (0)13.1 ± 1.220.1 ± 1.2
27 /7 (0)15.0 ± 3.021.6 ± 3.1
37 /7 (0)11.4 ± 0.318.0 ± 0.9
LTR7247 /7 (0)10.8 ± 0.816.6 ± 0.6
LTR72+ TRP-2181–200410 /10 (0)14.2 ± 3.621.3 ± 3.7
  • a Mice were injected s.c. in the right flank with 100 μl of one of the following vaccines: PBS, 2 × 105 unpulsed, or TRP-2181–188-pulsed DC, 100 μg TRP-2 DNA, or vector only. For mucosal vaccination, mice were intranasally exposed to 100 μl of the LTR72 (6 μg)-TRP-2181–200 (60 μg) mixture or to the LTR72 toxin only (6 μg). Vaccinated mice were challenged s.c. with 5 × 104 B16 cells 1 wk (for mucosal vaccination) or 2 wk (for the other vaccination procedures) after the last vaccine boost.

  • b Mice received the indicated number of vaccine boosts.

  • c Numbers represent tumor-bearing animals/total number of animals at day 60 after the challenge. The percentage of tumor-free animals is reported in parenthesis.

  • d Numbers indicate the arithmetic mean ± SE of the time of appearance of the tumor. Results of the statistical analysis are reported in the legend to Fig. 2.

  • e Numbers indicate the arithmetic mean ± SE of the survival time of the challenged animals. Statistical comparison, carried out by the log-rank test, of the survival curves of mice injected three times with DC or TRP-2181–200-pulsed DC gave the following result: p < 0.0003. In all other vaccination conditions, the comparison was not statistically significant.